~ Buy the INOMAX (nitric oxide) Drug Profile, 2024 PDF Report in the Report Store ~

INOMAX Drug Patent Profile

✉ Email this page to a colleague

When do Inomax patents expire, and when can generic versions of Inomax launch?

Inomax is a drug marketed by Mallinckrodt Hosp and is included in one NDA. There are seventeen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twelve patent family members in fifteen countries.

The generic ingredient in INOMAX is nitric oxide. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the nitric oxide profile page.

DrugPatentWatch^® Generic Entry Outlook for Inomax

Inomax was eligible for patent challenges on December 23, 2003.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for INOMAX?
What are the global sales for INOMAX?
What is Average Wholesale Price for INOMAX?

Summary for INOMAX

International Patents:	112
US Patents:	17
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	17
Clinical Trials:	15
Drug Prices:	Drug price information for INOMAX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INOMAX
What excipients (inactive ingredients) are in INOMAX?	INOMAX excipients list
DailyMed Link:	INOMAX at DailyMed

Drug patent expirations by year for INOMAX

Recent Clinical Trials for INOMAX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Massachusetts General Hospital	N/A
University of California, Los Angeles	Phase 2
Medical College of Wisconsin	Phase 2/Phase 3

See all INOMAX clinical trials

Pharmacology for INOMAX

Drug Class	Vasodilator
Physiological Effect	Vasodilation

Paragraph IV (Patent) Challenges for INOMAX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INOMAX	for Inhalation	nitric oxide	100 ppm and 800 ppm	020845	1	2014-05-20

US Patents and Regulatory Information for INOMAX

INOMAX is protected by six US patents.

Patents protecting INOMAX

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATING A PEDIATRIC PATIENT WHO IS EXPERIENCING IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION RESULTING IN OXYGEN DESATURATION, WHEREIN THE PATIENT IS NOT DEPENDENT ON RIGHT-TO-LEFT SHUNTING OF BLOOD

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Gas delivery device and system
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Gas delivery device and system
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Apparatus and method for monitoring nitric oxide delivery
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mallinckrodt Hosp	INOMAX	nitric oxide	GAS;INHALATION	020845-002	Dec 23, 1999		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
Mallinckrodt Hosp	INOMAX	nitric oxide	GAS;INHALATION	020845-003	Dec 23, 1999	AA	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
Mallinckrodt Hosp	INOMAX	nitric oxide	GAS;INHALATION	020845-003	Dec 23, 1999	AA	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
Mallinckrodt Hosp	INOMAX	nitric oxide	GAS;INHALATION	020845-002	Dec 23, 1999		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
Mallinckrodt Hosp	INOMAX	nitric oxide	GAS;INHALATION	020845-002	Dec 23, 1999		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
Mallinckrodt Hosp	INOMAX	nitric oxide	GAS;INHALATION	020845-003	Dec 23, 1999	AA	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up			Y	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for INOMAX

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mallinckrodt Hosp	INOMAX	nitric oxide	GAS;INHALATION	020845-003	Dec 23, 1999	⤷ Sign Up	⤷ Sign Up
Mallinckrodt Hosp	INOMAX	nitric oxide	GAS;INHALATION	020845-002	Dec 23, 1999	⤷ Sign Up	⤷ Sign Up
Mallinckrodt Hosp	INOMAX	nitric oxide	GAS;INHALATION	020845-002	Dec 23, 1999	⤷ Sign Up	⤷ Sign Up
Mallinckrodt Hosp	INOMAX	nitric oxide	GAS;INHALATION	020845-002	Dec 23, 1999	⤷ Sign Up	⤷ Sign Up
Mallinckrodt Hosp	INOMAX	nitric oxide	GAS;INHALATION	020845-003	Dec 23, 1999	⤷ Sign Up	⤷ Sign Up
Mallinckrodt Hosp	INOMAX	nitric oxide	GAS;INHALATION	020845-003	Dec 23, 1999	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

EU/EMA Drug Approvals for INOMAX

Subscribe to access the full database, or Sign Up
Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Linde Healthcare AB	INOmax	nitric oxide	EMEA/H/C/000337 INOmax, in conjunction with ventilatory support and other appropriate active substances, is indicated:for the treatment of newborn infants ≥34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation;as part of the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function and oxygenation.	Authorised	no	no	no	2001-08-01
>Company	>Drugname	>Inn	>Product Number / Indication	>Status	>Generic	>Biosimilar	>Orphan	>Marketing Authorisation	>Marketing Refusal

International Patents for INOMAX

When does loss-of-exclusivity occur for INOMAX?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 09202685
Estimated Expiration: ⤷ Sign Up

Patent: 10202422
Patent: Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
Estimated Expiration: ⤷ Sign Up

Patent: 10206032
Patent: Methods of treating patients having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
Estimated Expiration: ⤷ Sign Up

Patent: 12201382
Patent: Methods of treating patients having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
Estimated Expiration: ⤷ Sign Up

Patent: 15100638
Patent: Methods of treating patients having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
Estimated Expiration: ⤷ Sign Up

Patent: 15100783
Patent: Methods of treating patients having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
Estimated Expiration: ⤷ Sign Up

Patent: 15202617
Patent: Methods of treating patients having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
Estimated Expiration: ⤷ Sign Up

Patent: 15202618
Patent: Methods of treating patients having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
Estimated Expiration: ⤷ Sign Up

Patent: 16259420
Patent: Methods of treating patients having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
Estimated Expiration: ⤷ Sign Up

Patent: 17201628
Patent: Methods of treating patients having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
Estimated Expiration: ⤷ Sign Up

Patent: 17201630
Patent: Methods of treating patients having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
Estimated Expiration: ⤷ Sign Up

Patent: 17202301
Patent: Methods of treating patients having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
Estimated Expiration: ⤷ Sign Up

Patent: 18205119
Patent: Methods of treating patients having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
Estimated Expiration: ⤷ Sign Up

Patent: 20201590
Patent: Methods of treating patients having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
Estimated Expiration: ⤷ Sign Up

Patent: 22201219
Patent: Methods of treating patients having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
Estimated Expiration: ⤷ Sign Up

Canada

Patent: 71029
Patent: PROCEDES DESTINES AU TRAITEMENT DES NOUVEAU-NES A TERME OU PRESQUE A TERME ATTEINTS D'UNE INSUFFISANCE RESPIRATOIRE HYPOXIQUE ASSOCIEE A DES SIGNES CLINIQUES OU ECHOCARDIOGRAPHIQUES D'HYPERTENSION PULMONAIRE (METHODS OF TREATING TERM AND NEAR-TERM NEONATES HAVING HYPOXIC RESPIRATORY FAILURE ASSOCIATED WITH CLINICAL OR ECHOCARDIOGRAPHIC EVIDENCE OF PULMONARY HYPERTENSION)
Estimated Expiration: ⤷ Sign Up

Patent: 30908
Patent: PROCEDES DESTINES AU TRAITEMENT DES NOUVEAU-NES A TERME OU PRESQUE A TERME ATTEINTS D'UNE INSUFFISANCE RESPIRATOIRE HYPOXIQUE ASSOCIEE A DES SIGNES CLINIQUES OU ECHOCARDIOGRAPHIQUES D'HYPERTENSION PULMONAIRE (METHODS OF TREATING TERM AND NEAR-TERM NEONATES HAVING HYPOXIC RESPIRATORY FAILURE ASSOCIATED WITH CLINICAL OR ECHOCARDIOGRAPHIC EVIDENCE OF PULMONARY HYPERTENSION)
Estimated Expiration: ⤷ Sign Up

European Patent Office

Patent: 69614
Patent: Procédé d'identification d'une population de patients éligibles au traitement au monoxyde d'azote (A method of identifying a patient population suited to receiving nitric oxide)
Estimated Expiration: ⤷ Sign Up

Patent: 48572
Patent: PROCÉDÉS D'IDENTIFICATION D'UNE POPULATION DE PATIENTS ÉLIGIBLES POUR LE TRAITEMENT AVEC DE L'OXYDE NITRIQUE PAR INHALATION (METHODS OF IDENTIFYING A PATIENT POPULATION ELIGIBLE FOR TREATMENT WITH NITRIC OXIDE VIA INHALATION)
Estimated Expiration: ⤷ Sign Up

Patent: 40304
Patent: Procédés pour réduire le risque ou prévenir l'apparition d'un événement défavorable ou d'un événement défavorable grave associés au traitement par oxyde nitrique inhalé (Methods for reducing the risk or preventing the occurrence of an adverse event or serious adverse event associated with the inhalation of nitric oxide treatment)
Estimated Expiration: ⤷ Sign Up

Japan

Patent: 11010865
Patent: METHOD OF TREATING TERM AND NEAR-TERM NEONATE HAVING HYPOXIC RESPIRATORY FAILURE ASSOCIATED WITH CLINICAL OR ECHOCARDIOGRAPHIC EVIDENCE OF PULMONARY HYPERTENSION
Estimated Expiration: ⤷ Sign Up

Patent: 11011059
Patent: METHOD OF TREATING INFANT HAVING HYPOXIC RESPIRATORY FAILURE ASSOCIATED WITH CLINICAL OR ECHOCARDIOGRAPHIC OF EVIDENCE OF PULMONARY HYPERTENSION
Estimated Expiration: ⤷ Sign Up

Patent: 11251155
Patent: METHOD OF TREATING TERM AND NEAR-TERM NEONATE HAVING HYPOXIC RESPIRATORY FAILURE ASSOCIATED WITH CLINICAL OR ECHOCARDIOGRAPHIC EVIDENCE OF PULMONARY HYPERTENSION
Estimated Expiration: ⤷ Sign Up

Mexico

Patent: 10006055
Patent: METODOS DE TRATAMIENTO DE RECIEN NACIDOS Y CASI A PUNTO DE NACER QUE TIENEN FALLAS RESPIRATORIAS HIPOXICAS ASOCIADA CON EVIDENCIA CLINICA O ECOCARDIOGRAFICA DE HIPERTENSION PULMONAR. (METHODS OF TREATING TERM AND NEAR-TERM NEONATES HAVING HYPOXIC RESPIRATORY FAILURE ASSOCIATED WITH CLINICAL OR ECHOCARDIOGRAPHIC EVIDENCE OF PULMONARY HYPERTENSION.)
Estimated Expiration: ⤷ Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INOMAX around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Mexico	2010006055	METODOS DE TRATAMIENTO DE RECIEN NACIDOS Y CASI A PUNTO DE NACER QUE TIENEN FALLAS RESPIRATORIAS HIPOXICAS ASOCIADA CON EVIDENCIA CLINICA O ECOCARDIOGRAFICA DE HIPERTENSION PULMONAR. (METHODS OF TREATING TERM AND NEAR-TERM NEONATES HAVING HYPOXIC RESPIRATORY FAILURE ASSOCIATED WITH CLINICAL OR ECHOCARDIOGRAPHIC EVIDENCE OF PULMONARY HYPERTENSION.)	⤷ Sign Up
Japan	2004167284		⤷ Sign Up
Japan	3718491		⤷ Sign Up
New Zealand	739614	Gas delivery device and system	⤷ Sign Up
Greece	3024865		⤷ Sign Up
Japan	2020187129	一酸化窒素に曝される電気化学ガスセンサーの長期の感度変動を補償する方法 (METHOD FOR COMPENSATING LONG TERM SENSITIVITY DRIFT OF ELECTROCHEMICAL GAS SENSORS EXPOSED TO NITRIC OXIDE)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for INOMAX

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1516639	300327	Netherlands	⤷ Sign Up	300327, 20111205, EXPIRES: 20160731
0786264	CA 2008 00019	Denmark	⤷ Sign Up
1516639	C300327	Netherlands	⤷ Sign Up	PRODUCT NAME: STIKSTOFMONOXIDE; REGISTRATION NO/DATE: EU/1/01/194/001 20010801
1516639	CA 2007 00072	Denmark	⤷ Sign Up
0786264	SPC/GB08/019	United Kingdom	⤷ Sign Up	PRODUCT NAME: NITRIC OXIDE (NO); REGISTERED: UK EU/1/01/194/001 20010801
0560928	SPC/GB02/009	United Kingdom	⤷ Sign Up
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description